[go: up one dir, main page]

WO2006105538A3 - Methods and compositions for treating il-21 related pathologies - Google Patents

Methods and compositions for treating il-21 related pathologies Download PDF

Info

Publication number
WO2006105538A3
WO2006105538A3 PCT/US2006/012749 US2006012749W WO2006105538A3 WO 2006105538 A3 WO2006105538 A3 WO 2006105538A3 US 2006012749 W US2006012749 W US 2006012749W WO 2006105538 A3 WO2006105538 A3 WO 2006105538A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
treating
compositions
related pathologies
ige
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/012749
Other languages
French (fr)
Other versions
WO2006105538A2 (en
Inventor
Keying Ma
Xiao-Yu Song
Donald E Grisworld
Xiaozhou Shang
Li Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of WO2006105538A2 publication Critical patent/WO2006105538A2/en
Anticipated expiration legal-status Critical
Publication of WO2006105538A3 publication Critical patent/WO2006105538A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to methods for treating at least one IL-21 related condition or pathology, including therapeutic compositions, methods and devices, wherein said patholog involves the increase in IgE production or IgE isotype switching.
PCT/US2006/012749 2005-03-31 2006-03-31 Methods and compositions for treating il-21 related pathologies Ceased WO2006105538A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66678405P 2005-03-31 2005-03-31
US60/666,784 2005-03-31

Publications (2)

Publication Number Publication Date
WO2006105538A2 WO2006105538A2 (en) 2006-10-05
WO2006105538A3 true WO2006105538A3 (en) 2009-04-23

Family

ID=37054232

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/012749 Ceased WO2006105538A2 (en) 2005-03-31 2006-03-31 Methods and compositions for treating il-21 related pathologies

Country Status (1)

Country Link
WO (1) WO2006105538A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1963369T3 (en) 2005-11-28 2013-10-31 Zymogenetics Inc Il-21 antagonists
WO2009047360A1 (en) * 2007-10-11 2009-04-16 Novo Nordisk A/S Il-21 antibodies
ES2584237T3 (en) 2007-12-07 2016-09-26 Zymogenetics, Inc. Human anti-IL-21 monoclonal antibodies
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
PT3636274T (en) 2011-01-18 2024-10-17 Bioniz Therapeutics Inc Compositions and methods for modulating gamma-c-cytokine activity
CA2915882C (en) 2013-06-27 2022-12-06 Monash University Il-21 binding proteins and uses thereof
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
PT3104853T (en) 2014-02-10 2020-01-14 Respivant Sciences Gmbh TREATMENT WITH MASTOCYTE STABILIZERS FOR SYSTEMIC DISORDERS
CA2938996A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the treatment of lung diseases with mast cell stabilizers
US10940212B2 (en) 2014-12-19 2021-03-09 Monash University IL-21 agonist antibodies and methods of treatment using same
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
ES2884357T3 (en) 2015-10-09 2021-12-10 Bioniz Llc Modulation of gamma-c cytokine activity
JP2019528320A (en) 2016-08-31 2019-10-10 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ Cromolyn composition for the treatment of chronic cough due to idiopathic pulmonary fibrosis
EP3522983A4 (en) 2016-10-07 2020-06-03 Respivant Sciences GmbH Cromolyn compositions for treatment of pulmonary fibrosis
WO2020227019A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAVEN ET AL.: "rHull-21 Enhances IgE Production in Human PBMC and Purified Tonsilar B Cellls Stimulated with IL-4 and alphaCD40 in a Cell Number, IL Concentration, and Proliferation Dependent Manner.", FASEB JOURNAL, vol. 18, no. 4-5, 2004, pages A1125 *
OZAKI ET AL.: "A Critical Role for IL-21 in Regulating Immunoglobulin Production.", SCIENCE., vol. 298, November 2002 (2002-11-01), pages 1630 - 1634 *
SHANG ET AL.: "IL-2 but not IFN-g production in a mouse model of allergy.", FASEB JOURNAL., vol. 19, no. 4, March 2005 (2005-03-01), pages A939 *
SUTO ET AL.: "Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line Ce ranscription of IL-4-stimulated B cells.", BLOOD., vol. 100, no. 13, December 2002 (2002-12-01), pages 4565 - 4573 *
WOOD ET AL.: "IL-21 efects on human IgE production in response to IL-4 or IL-13.", CELLULAR IMMUNOLOGY., vol. 231, 2004, pages 133 - 145 *

Also Published As

Publication number Publication date
WO2006105538A2 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
WO2005091853A3 (en) Methods and compositions for treating il-13 related pathologies
WO2006003388A8 (en) Compositions and methods for treating inflammatory disorders
WO2008070692A8 (en) Bicyclic compounds and use as antidiabetics
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
WO2009023509A3 (en) Therapeutic combinations useful in treating cftr related diseases
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2007007173A3 (en) Human anti-madcam antibodies
PL1960600T3 (en) Tissue product treated with additive composition, and method for the production thereof
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2006096490A8 (en) ANTI-MAdCAM ANTIBODY COMPOSITIONS
WO2006105538A3 (en) Methods and compositions for treating il-21 related pathologies
WO2007022506A3 (en) Methods and compositions for treating neurological disease
WO2007022529A3 (en) Method of treating inflammatory diseases
IL184524A0 (en) Substituted pyrazolo-pyridines, compositions containing them, method for the production thereof, and their use
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2008046581A3 (en) Substituted tetrahydropyrrolopyrazine compounds and use thereof in medicaments
WO2006127900A3 (en) Tl1a in the treatment of disease
EP1908749A4 (en) Process for production of isocyanate, isocyanate produced by the process, and use of the isocyanate
WO2006136357A3 (en) Crystalline modifications to pyraclostrobin
WO2008066630A3 (en) Methods for reprogramming adult somatic cells and uses thereof
WO2008027600A3 (en) Imatinib compositions
WO2005044200A3 (en) Methods and compositions for treating mcp-1 related pathologies
IL176420A0 (en) Process for the manufacture of 2,3-dichloropyridine
WO2007144057A3 (en) Antimicrobial carbon
WO2009115252A3 (en) Substituted pyrazolamides and the use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06749378

Country of ref document: EP

Kind code of ref document: A2